The likelihood of regulatory delays as a consequence of the coronavirus outbreak is high, according to a recent poll conducted by Verdict.

A majority 62% of the poll respondents said that the delays are very likely, while 19% opined that the delays are ‘somewhat likely’.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Delays are unlikely, according to just 19% of the respondents.

The analysis is based on 679 responses received during the poll period from 26 March to 02 April.

Regulatory delays-coronavirus outbreak

The coronavirus outbreak is also expected to cause clinical trial delays, according to another poll run by Verdict during the same period.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact